Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis and commercialisation of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts.
These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with the Caldicott Principles, UK data protection law and applicable regulatory guidance.
From this analysis, the Company seeks to discover new insights that improve patient care and are of significant value to Pharmaceutical Companies throughout the research, development and commercialisation process for medicines.
Sensyne Health has been set up to be an exemplar of how a commercial company can partner with the NHS to improve patient care and generate value from anonymised patient data in an ethical way. The Company acts as an interface between the NHS and Pharmaceutical Companies.
Sensyne Health also generates data from its own digital health software products that are being used by a number of NHS Trust customers. The Company has lead discovery programmes in the following broad therapeutic areas: (i) respiratory diseases; (ii) cardiovascular diseases; (iii) neurological diseases and (iv) immunological diseases and cancer.
Sensyne Health’s business strategy is built upon three pillars:
- access to a large data library comprising multiple datasets of ethically sourced, clinically curated anonymised patient data across large patient populations that have the critical mass and structure to enable analysis using Clinical AI of real-world evidence across a wide range of therapeutic areas, including all of the lead discovery programmes currently being pursued by the Company;
- a portfolio of proprietary Clinical AI technologies that combine leading medical and engineering science expertise developed through a longstanding research partnership between the University of Oxford and OUH NHS Foundation Trust; and
- a “double-bottom line” business strategy that provides a financial return back to the NHS Trusts that partner with the Company via equity ownership in the Company and a share of royalties.